Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

517
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
517
Dementia01:30

Dementia

487
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
487
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing-dependent protective and therapeutic effects of ethyl pyruvate in trinitrobenzene sulfonic acid-induced experimental colitis.

Experimental physiology·2026
Same author

Microfluidics-based engineered silver nanoparticles to control growth and biofilm formation in bacterial pathogens causing dental infection.

Scientific reports·2026
Same author

Noteworthy compatibility of microbial consortium mediated microplastics degraded metabolites with physiochemical, biological, including microbiological parameters of diverse aquatic media.

World journal of microbiology & biotechnology·2026
Same author

Metabolomic analysis of <i>Pennisetum glaucum</i> seed extracts using advanced LC-MS/MS and Q-TOF technology.

Journal of food science and technology·2026
Same author

Pyrazole-Cyclotriphosphazene Hybrids: Synthesis, Structural Insights, and Cytotoxic Effects against Pancreatic Cancer Cells.

ACS omega·2026
Same author

K-STAMM: a knowledge-enhanced spatial - temporal attention model with multimodal fusion for pneumonia prediction.

Scientific reports·2026

Related Experiment Video

Updated: Jan 10, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.8K

Precision therapeutics for Alzheimer's disease.

S Priyanka1, T Manjari1, S Hemalatha1

  • 1PG & Research Department of Chemistry, Bishop Heber College, Trichy, India.

Progress in Brain Research
|November 28, 2025
PubMed
Summary

Precision medicine offers tailored Alzheimer's disease (AD) treatments by considering individual profiles. This approach explores advanced therapies like gene editing and monoclonal antibodies for better outcomes.

Keywords:
Alzheimer’s diseaseBiomarkersGene editingMonoclonal antibodiesPrecision medicineStem cell therapy

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.8K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.9K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with significant cognitive decline.
  • Current treatments for AD are limited, highlighting the need for novel therapeutic strategies.
  • The accumulation of amyloid-beta plaques and tau tangles are hallmarks of AD pathology.

Purpose of the Study:

  • To explore advancements in precision therapeutics for Alzheimer's disease.
  • To discuss the potential of individualized treatment strategies in managing AD.
  • To review emerging and innovative therapeutic approaches for AD.

Main Methods:

  • Review of current literature on precision medicine in AD.
  • Analysis of biomarker-driven therapies and pharmacogenomics.
  • Exploration of novel therapeutic agents including monoclonal antibodies, RNA-based therapeutics, stem cells, and gene editing.

Main Results:

  • Precision medicine enables customized interventions based on genetic, molecular, and lifestyle factors.
  • Biomarker-driven therapies, pharmacogenomics, and targeted agents show promise for AD treatment.
  • Emerging innovations like RNA therapeutics, stem cells, and CRISPR offer new avenues for AD management.

Conclusions:

  • Precision medicine holds significant promise for developing effective, individualized Alzheimer's disease treatments.
  • Addressing challenges in clinical translation, patient stratification, and regulation is crucial for successful implementation.
  • Integrating cutting-edge research with clinical practice is key to advancing personalized AD care.